HighTower Advisors’s Nymox Pharmaceutical Corp NYMX Stock Holding History

HighTower Advisors’s Portfolio NYMX Stock Details NYMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-12,000	Closed	-$28K	–	2565
2020 Q1	$28K	Hold	12,000	–	–	﹤0.01%	2056
2019 Q4	$27K	Sell	12,000 -2,000	-14%	-$3.95K	﹤0.01%	2151
2019 Q3	$26K	Sell	14,000 -400	-3%	-$700	﹤0.01%	2253
2019 Q2	$19K	Buy	+14,400	New	+$25.2K	﹤0.01%	2266
2016 Q3	–	Sell	-11,200	Closed	-$36K	–	1972
2016 Q2	$36K	Hold	11,200	–	–	﹤0.01%	1659
2016 Q1	$28K	Buy	+11,200	New	+$26.5K	﹤0.01%	1987

Other funds holding NYMX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FDCDDQ

Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

STRS Ohio Columbus, Ohio $25.2B AUM 30.31% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

HighTower Advisors's NYMX Position: Q2 2020 in Review

HighTower Advisors sold out of Nymox Pharmaceutical Corp (NYMX) in Q2 2020, closing a stake of 12,000 shares — an estimated $28K sold.

HighTower Advisors first reported a position in NYMX in Q1 2016 and held it in 6 quarters. The position peaked at $36K in Q2 2016. 63 funds tracked by Wall St. Rank hold NYMX as of Q2 2020.

HighTower Advisors reported no remaining Nymox Pharmaceutical Corp position as of Q2 2020 after selling out during the quarter.
HighTower Advisors sold 12,000 Nymox Pharmaceutical Corp shares in Q2 2020, an estimated $28K.
HighTower Advisors first reported a position in Nymox Pharmaceutical Corp in Q1 2016 and held it in 6 quarters.
HighTower Advisors's Nymox Pharmaceutical Corp position peaked at $36K in Q2 2016.
63 funds tracked by Wall St. Rank held Nymox Pharmaceutical Corp as of Q2 2020.

Based on HighTower Advisors's 13F filing for Q2 2020, filed 10 Aug 2020.